❦ I have seen a disproportionate number of young patients with advanced cancer over the last two years.

They used to stand out: now it’s every week.

The evidence points to direct Covid-driven mechanisms for rises in cancer risk.

Will you hear about it in the news? Of course not. Covid’s over.

It’s just anxiety now if you’re thinking about it.

Except it’s not. It’ll take years for people to accept this. It’ll be too late.

A number of my oncology colleagues have been commenting on how they’ve never seen such aggressively-progressive cancers in all their careers since Covid arrived.

I’ve been seeing it as all these patients come to me.

It isn’t normal. Alarm bells should be ringing loudly.

The evidence:

📖 (22 Mar 2023 ~ Global Journal of Life Sciences and Biological Research) Cancer Related-Genes Enriched in Peripheral Blood Mononuclear Cells (PBMCs) of COVID-19 Patients: A Bioinformatics Study ➤

 
‘SARS-CoV-2 can be considered a potential risk factor for increasing the probability of developing cancer.’

Study 1:

📖 (7 Jun 2022 ~ Frontiers in Oncology) SARS-CoV-2 M Protein Facilitates Malignant Transformation of Breast Cancer Cells ➤

‘Coronavirus disease 2019 (COVID-19) has spread faster due to the emergence of SARS-CoV-2 variants, which carry an increased risk of infecting patients with comorbidities, such as breast cancer.’

Study 2:

📖 (9 Aug 2022 ~ Journal of Infection) Is SARS-CoV-2 an oncogenic virus? ➤

‘Gene expression of p53 [tumour suppressor] is downregulated in blood of COVID-19 patients.

Downregulation persists at least 24 weeks after infection in long COVID-19 patients.

Long-term reduction of p53 could have impact on carcinogenesis.’

📖 (9 Aug 2022 ~ Journal of Infection) Letter to the editor: Is SARS-CoV-2 an oncogenic virus? ➤

Study 3:

📖 (22 Mar 2023 ~ Global Journal of Life Sciences and Biological Research) Cancer related-genes enriched in peripheral blood mononuclear cells (PBMCs) of COVID-19 patients. A bioinformatics study ➤

‘Numerous cancer-related genes up-regulated in SARS-CoV-2-infected patients, particularly those genes participating in the cell-cycle regulation or engaged in cellular senescence processes.’

Study 4:

📖 (2 Jun 2023 ~ Biochimie) Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? ➤

‘One of the most worrying long-term effects of infection is the potential to induce malignant neoplasms, which will be a major health concern over the coming decades.

SARS-CoV-2 infection affects many mechanisms that play a crucial role in cancer onset and progression including cell-cycle regulation, the RAAS system and inflammation / proliferation signaling pathways.’

❂

Related reading:

📖 (9 Aug 2021 ~ Nature: Scientific Reports) More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis ➤

📖 (21 Jun 2021 ~ Nature: Scientific Reports) The risk of pancreatic adenocarcinoma following SARS-CoV family infection ➤

📖 (4 Mar 2021 ~ Nature: Scientific Reports) COVID-19 engages clinical markers for the management of cancer and cancer-relevant regulators of cell proliferation, death, migration, and immune response ➤

📖 (28 Jan 2021 ~ Nature: Scientific Reports) Meta-analysis of host transcriptional responses to SARS-CoV-2 infection reveals their manifestation in human tumors ➤

📖 (25 Jan 2010 ~ Nature: Oncogene) Viral epigenome in human tumorigenesis ➤

📖 (Dec 2006 ~ Yale Journal of Biology and Medicine) Viruses and human cancer ➤

❂

© 2023 NHS Medical Consultant.